Experts have warned the possible takeover of UK pharmaceutical firm AstraZeneca by US drugs giant Pfizer could damage development of new drugs  In a statement four scientific bodies say recent mergers and acquisitions have led to lab closures threatening the research base The statement is from the Society of Biology Biochemical Society British Pharmacological Society and Royal Society of Chemistry They have more than  members  In addition Dr Melanie Lee a fellow of the Academy of Medical Sciences said the move could be a nail in the coffin of the UK drug industry And Adrian Bailey Labour MP and chair of the Commons Business Innovation and Skills Select Committee said he is considering an inquiry into the issue The joint statement says that the proposed acquisition is another sign of the global trend for pharmaceuticals  It says The UK has been a worldleader in medicines research and development but recent closures and restructuring put this position under threat  Pfizer sold its UKbased research facilities in Sandwich Kent in  with the loss of  jobs many of which were highly skilled It has also closed laboratories of US companies that it has acquired The companys track record has raised concerns that it may do the same with AstraZenecas research facilities  which many regard as a strategic national asset  AstraZeneca is the UKs second biggest industrial spender on RD investing bn last year In the UK it has eight sites and about  employees  Dr Mark Downs chief executive of the Society of Biology told BBC News that RD was critical to the UK He said We have been been a world leader in pharmaceutical research producing many of the worlds best selling medicines  But if restructuring continues in a way where we lose skills and investment that will be detrimental to everybody We cant let this drift  In a statement earlier this week Pfizers Chairman and CEO Ian Read said he and his executives have great respect for AstraZeneca The UK has created attractive incentives for companies to manufacture products and maintain and protect intellectual property and we have seen that capital and jobs have followed these types of incentives Professor Sir Richard Sykes chairman of the Royal Institution and a former head of the UK drugs giant GSK said he didnt believe that Pfizer would close research facilities in the UK  I think it would be rather stupid of them to close AstraZenecas state of the art facilities With the opportunity to build the big science base they have in an area like Cambridge around one of the top science groups in the world they would be crazy not to do that and they will jump at that opportunity However many leading scientific bodies have expressed serious concerns to Downing Street and the Treasury  Dr Lee said the potential takeover of AstraZeneca by Pfizer would not present a positive move for the UK science base nor AstraZenecas RD It is likely to involve reducing RD investment across the combined group   The UK scientific community and government should ask very serious questions about this proposal and understand fully that this could be a further nail in the coffin of our UK based pharmaceutical industry Professor Sir John Savill chief executive of the Medical research Council said he hoped that the collaborative culture that AstaZeneca has developed in the UK is maintained and strengthened This would benefit both health and wealth in the UK Mr Bailey told BBC News that he will ask his committee to launch an inquiry into whether Astra Zenecas research facilities will be safe should Pfizer acquire the firm The committee will want to make some sort of or intervention inquiry into this issue Here we have a British Company being taken over by an American company that closed down its operations in Britain a couple of years ago Before there is any takeover we would want to have some sort of scrutiny into whether the takeover would be detrimental to AstraZenecas position in this country A spokesman for Pfizer said We have not closed our UK based research facilities in Sandwich The Sandwich site was sold to Discovery Park Limited in  However we continue to be a major tenant at Discovery Park and have around  research and development colleagues based at the site working on Pfizers mid to late stage development pipeline and developing medicines for clinical trials in a wide range of disease areas including cancer and diabetes